Down-regulation of PTEN and oncogenic mutation of PIK3CA compounded with EGFR over expression has been correlated with poor response to trastuzumab treatment as well as a poor clinical outcome in women with HER2+ breast cancer (88, 89). The gene discussed is EGFR; the disease is breast cancer.